U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601711) titled 'Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study' on March 29.
Brief Summary: This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.
The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical vent...